Co-Authors
This is a "connection" page, showing publications co-authored by Shuai Xia and Zezhong Liu.
Connection Strength
1.101
-
RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response. Signal Transduct Target Ther. 2020 11 27; 5(1):282.
Score: 0.229
-
The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin. Signal Transduct Target Ther. 2020 06 12; 5(1):92.
Score: 0.222
-
Inefficiency of Sera from Mice Treated with Pseudotyped SARS-CoV to Neutralize 2019-nCoV Infection. Virol Sin. 2020 06; 35(3):340-343.
Score: 0.219
-
Potent MERS-CoV Fusion Inhibitory Peptides Identified from HR2 Domain in Spike Protein of Bat Coronavirus HKU4. Viruses. 2019 01 14; 11(1).
Score: 0.201
-
Repurposing of a clinically used anti-HPV agent to prevent and treat SARS-CoV-2 infection as an intranasal formulation. Signal Transduct Target Ther. 2021 08 26; 6(1):318.
Score: 0.060
-
A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases. Acta Pharm Sin B. 2021 Aug 02.
Score: 0.060
-
Retraction Note to: SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion. Cell Mol Immunol. 2020 08; 17(8):894.
Score: 0.056
-
RETRACTED ARTICLE: SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion. Cell Mol Immunol. 2020 04 07.
Score: 0.055